Trident Lifeline has completed acquisition of additional 50.49% of the total issued and paid-up share capital of TLL Parenterals (TPL), by way of new allotment of equity shares and making TPL as a subsidiary of the Company.
This acquisition would allow the company to partner with the leading and fast-growing market of organic and inorganic chemicals along with pharmaceuticals and allied products.
Trident Lifeline is engaged in the manufacturing and marketing of quality finished dosages.